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1. Introduction 
Neuroblastoma is a common tumor of the childhood arising from embryonal sympathetic 
neural cell precursors. Despite of the improved therapeutic strategies, the survival rate of 
high-risk neuroblastoma patients is poor. Although complete clinical remissions can be 
achieved, relapse is relatively frequent, indicating a role for the persistence of the minimal 
residual disease (for review, Maris, 2010). Treatments with derivatives of retinoic acid (RA), 
the biologically active form of vitamin A, produce significant improvements on the therapy 
of high-risk neuroblastoma patients, when used together with intensive multimodal 
therapies (Reynolds et al., 2003, for review). Despite some controversy on dosage and 
treatment schedules (Matthay & Reynolds, 2000; Reynolds et al., 2003), treatment with 13-
cis-RA (isotretinoin) has been reported to produce a modest but significant increase in the 
event-free survival of high-risk neuroblastoma patients (Matthay et al., 2009; Matthay et al., 
1999). RA and its derivatives, the retinoids, are differentiating agents that induce growth 
arrest, differentiation and/or apoptosis of neuroblastoma cells in vitro (Lovat et al., 1997; 
Pahlman et al., 1984; Sidell, 1982; Thiele et al., 1985). However the molecular bases of RA 
therapeutic actions in neuroblastoma have not been established yet. 
With the aim of identifying possible molecular targets for RA treatment, we have analyzed 
RA-induced gene expression changes in SH-SY5Y cultured human neuroblastoma cells 
(Lopez-Carballo et al., 2002), by means of Ordered Differential Display RT-PCR (Matz et al., 
1997). Among more than 60 genes identified, we could found LAMR1 (also called RPSA), 
encoding the precursor for the 67-KDa Laminin Receptor (67LR) (Wewer et al., 1986; Yow et 
al., 1988), whose mRNA levels were remarkably reduced after RA treatment. The 67LR is a 
multifunctional protein which is involved in cell adhesion, required for maintaining of cell 
viability (Scheiman et al., 2010; Susantad & Smith, 2008), acts as receptor for infectious 
agents like viruses and prions (Vana et al., 2009) and mediates the actions of the green tea 
polyphenol epigallocatechin-3-gallate (Umeda et al., 2008). Expression of 67LR has been 
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correlated with the biological aggressiveness, and the invasive and metastatic capacities of 
tumors from diverse origin. Many examples in which the expression of 67LR is increased in 
a tumor in respect to the corresponding normal tissue have been reported, and elevated 
expression of 67LR correlates with tumor progression and has been considered as adverse 
prognostic factor in several human cancers (Castronovo, 1993; Menard et al., 1997; Menard 
et al., 1998; Viacava et al., 1997, for review). LAMR1 encodes a 37 KDa precursor protein 
(Wewer et al., 1986; Yow et al., 1988), that is acylated and glycosylated to generate the 
mature 67LR (Buto et al., 1998; Katagiri et al., 2005; Landowski et al., 1995) A role of 67LR in 
stabilizing the binding of integrins to laminin has been postulated (Magnifico et al., 1996), 
and it has been proposed that binding of 67LR contributes to laminin remodeling, thereby 
facilitating laminin degradation by proteolytic enzymes and increasing the release of 
motility fragments (Ardini et al., 2002; Berno et al., 2005; Vande Broek et al., 2001). 
Therefore, 67LR could play a role in the degradation of basal membrane whose major 
component is laminin, a critical step of the metastasis process and a prerequisite for tumor 
vascularization, involving the invasion of tumor mass by endothelial cells. 
We report here that RA treatment of human neuroblastoma cells induces a reduction on the 
mRNA and protein levels of 67LR. In parallel, RA treatment impaired neuroblastoma cell 
migration towards laminin in haptotaxis assays in vitro and reduced invasiveness through 
Matrigel in in vitro invasion assays, processes in which 67LR played a major role. In addition, 
we show by immunohistochemical methods that more than two thirds of the human high-
risk neuroblastic tumors assayed expressed 67LR to certain extent. The results showed here 
support an important role for 67LR in migration towards and invasion through the 
basement membrane, critical steps on the metastasis process. RA-induced downregulation 
of 67LR correlates with a reduction in the biological aggressiveness in vitro of neuroblastoma 
cells, and supports the idea of 67LR as an important molecular target for the therapeutic 
actions of RA in neuroblastoma. 
2. Experimental procedures 
2.1 Cell culture and treatments 
SH-SY5Y cells (ATCC no. CRL-2266) were cultured in DMEM containing 10% heat-inactivated 
FBS, 100 U/ml penicillin and 100 g/ml streptomycin. LA-N-1 cells (ECACC no. 06041201) 
were grown in a 1:1 mixture of EMEM and Ham’s F-12 medium containing 10% heat-
inactivated FBS, 100 U/ml penicillin, 100 g/ml streptomycin and 1% non-essential amino 
acids. Cell cultures were kept in a humidified incubator at 37ºC with 5% CO2. The medium 
was replaced every 2 days and the cells were split before they reached confluence. 
Cycloheximide (CHX), all-trans-retinoic acid (RA), and LY294002 (LY) were purchased from 
Sigma. The different compounds were dissolved in Dimethyl-sulfoxide and added to the 
culture medium at the indicated concentrations. Peptide P11 (Ac-CDPGYIGSR-NH2, (Graf et 
al., 1987b) and its Scrambled control (Ac-YCIPGDRGS-NH2) were synthesized and purified by 
HPLC to >90%. Peptides were dissolved in serum-free culture medium at 60 g/ml (60 M). 
2.2 RNA analysis 
Northern Blot analysis of total RNA from SH-SY5Y cells with [32P]-labeled probes were 
performed as previously described (Lopez-Carballo et al., 2002). LAMR1 probe consisted of 
a 1 Kb fragment obtained from the EST clone IMAGE 1271323. Probes for Cyclophilin A 
(PPIA) and beta-actin (ACTB) consisted in cDNA fragments generated by RT-PCR. For 
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quantification of the LAMR1 expression levels, duplicate Northern Blots were exposed to 
Fuji IP capture plates, measured using a Fuji FLA-5000 laser scanner and analyzed using 
Fuji ImageQuant software. LAMR1 absolute values were normalized to the values obtained 
for ACTB. 
2.3 Western blot 
Whole cell extracts were obtained by lysis of the cells in RIPA buffer (50 mM Hepes pH 7.4, 
150 mM NaCl, 1.5 mM MgCl2, 1 mM EGTA, 10% Glycerol) containing 0.5% Nonidet P-40, 
0.1% SDS, protease inhibitors (1 mM PMSF, 40 g/ml aprotinin and 40 g/ml leupeptin) 
and phosphatase inhibitors (1 mM sodium ortovanadate, 1 mM NaF). After 10 min 
incubation on ice, the lysate was cleared by centrifugation (16,100xg, 10 min, 4ºC), and 
protein concentration determined. Extracts were diluted with 2x sample buffer containing 
freshly added 50 mM Dithiothreitol. Western blot analysis of proteins from whole cell 
extracts was performed as described (Lopez-Carballo et al., 2002). Antibodies against the 67-
KDa Laminin Receptor (Wewer et al., 1987), were obtained from Abcam. Monoclonal 
antibodies against the 37-KDa Laminin Receptor precursor (MPLR, Buto et al., 1997) were a 
generous gift of Dr. S. Menard (Istituto Nazionale Tumori, Milan, Italy). Antibodies against 
beta-actin were purchased from Sigma. Horseradish-peroxidase-conjugated secondary 
antibodies were obtained from GE Healthcare, and Jackson ImmunoResearch. 
Chemiluminiscent signals were developed with ECL (GE Healthcare). 
2.4 Immunofluorescence 
SH-SY5Y neuroblastoma cells were treated with RA or vehicle for 96 h, scraped from the 
plate and washed in PBS. A drop of the cell suspension was applied onto poly-lysine-coated 
slides and let to settle for 10 min at room temperature. The slides were fixed with 4% 
paraformaldehyde in PBS for 20 min, and washed three times with PBS. After blocking with 
3% Bovine Serum Albumin in Phosphate Buffered Saline (PBS) for 40 min, slides were 
sequentially incubated with Anti-67-KDa Laminin Receptor (Abcam, diluted 1:50 in the 
same buffer) and Fluorescein-isothiocyanate (FITC)-conjugated anti-rabbit IgG (Jackson 
ImmunoResearch, diluted 1:100 in the same buffer). After washing with PBS, the slides were 
counter-stained with Hoechst 33258 (Scharlab, 50 mg/ml) for 5 min, rinsed with PBS and 
mounted with anti-fade mounting medium (Dako-Cytomation). Slides were sequentially 
photographed in a Leica fluorescence microscope equipped with FITC- and UV-specific 
excitation filters. 
2.5 Migration and invasion assays 
The effects of RA treatments, and Laminin 1-derived peptide P11 on the migration and 
invasion capacities of SH-SY5Y neuroblastoma cells were tested according to published 
protocols (Albini et al., 1987; McCarthy et al., 1983), with slight modifications. A modified, 
light-opaque Boyden chamber (Falcon HTS FluoroBlok, 8 m pore size; Becton-Dickinson) 
was used in both migration and invasion assays. Cells were treated with 1 M RA or vehicle 
in culture medium during the indicated times, and labeled in the plate with Calcein AM (5 
M; Molecular Probes-Invitrogen), during 30 min at 37ºC. Labeled cells were detached from 
the plate by scraping and counted. Migration/haptotaxis assays (see Fig. 3A) were used to 
measure cell movement toward an immobilized laminin-rich extracellular matrix protein 
gradient. For that purpose, the lower chamber of the plate was coated with BD Matrigel 
www.intechopen.com
 
Neuroblastoma – Present and Future 
 
220 
Matrix (10 g/cm2; Becton Dickinson) as attractant and filled with serum-free medium. 
50,000 labeled cells in serum-free medium were added onto the upper chamber. As control, 
equivalent experiments in which coating with Matrigel was omitted were set. After 6h of 
incubation at 37ºC, the fluorescent light emitted by the cells that migrated through the 
opaque filter was measured with a Victor2 multilabel counter (PerkinElmer Life and 
Analytical Sciences). The assays were performed at least in triplicate. For invasion assays 
(see Fig. 3C) the porous membrane of the Boyden chamber was covered with BD Matrigel 
matrix (5 g/cm2 in serum-free medium; Becton Dickinson) and allowed to gel for 30 min. 
50,000 calcein-labeled cells were carefully layered on top of the Matrigel layer and culture 
medium containing 10% FBS as chemoattractant to promote cell invasion was placed into 
the lower well. The fluorescent light emitted by cells in the lower chamber after 6 h 
incubation at 37ºC was measured in triplicate assays as above. Peptide blocking of 67LR was 
performed by incubating 50,000 labeled cells in 500 l of serum-free medium with P11 
peptide or Scrambled control peptide (60 g/ml; 60M) for 30 min at 37ºC and added to the 
upper chamber of migration/haptotaxis or invasion assays prepared as described above. For 
statistical analysis, one-way ANOVA together with Tukey post-hoc test were employed. 
2.6 Immunocytochemistry 
Immunohistochemical study was performed following streptavidin-biotin method with 
antigen retrieval using citrate buffer 0.1M, pH 6.0 and heating with autoclave at 1.5 atm 
during 3 minutes. Primary antibody (Anti-67-KDa Laminin Receptor, Abcam) was diluted 
1:100. Positive controls include internal epithelial tissues as well as one case of invasive 
breast carcinoma. Negative controls consisted in substitution of the primary antibody by 
mouse ascites and/or PBS. Immunohistochemistry was performed on a tissue microarray 
composed of cylinders of 1.5 mm in diameter of 49 cases of Neuroblastoma  that was 
assembled using a manual tissue arrayer (MTA , Beecher Inc, USA) (Noguera et al., 2009). 
3. Results 
3.1 RA treatment of SH-SY5Y neuroblastoma cells results in downregulation of the 
expression of the metastasis-associated 67-KDa Laminin receptor 
To identify differentially expressed genes during RA treatment of human neuroblastoma 
cells we have used the Ordered Differential Display RT-PCR technique (Matz et al., 1997). 
One of the displayed fragments, showing strong downregulation after 24 h of RA treatment, 
was amplified and sequenced. The sequence obtained (data not shown) corresponded to the 
LAMR1 gene (also called RPSA), encoding the 67 KDa Laminin Receptor (67LR; Wewer et 
al., 1986; Yow et al., 1988). Because 67LR has been described as a metastasis-associated gene, 
whose expression levels are related to tumoral progression (Menard et al., 1997; Menard et 
al., 1998; Sobel, 1993) we decided to study the regulation of LAMR1 transcription by RA 
with some detail. As shown on the Northern Blot in Fig. 1a, LAMR1 expression levels were 
significantly reduced after a 24 h RA treatment. This delayed downregulation profile 
resembled that reported for the coordinate repression of the ID1, ID2 and ID3 HLH genes 
(Lopez-Carballo et al., 2002). 
As was the case for the ID genes, the mechanism by which RA downregulates LAMR1 
expression appears to be complex. The reduction on the levels of LAMR1 mRNA observed 
after 24 h of RA treatment did not occur when cells were pre-treated with the protein 
synthesis inhibitor Cycloheximide (CHX), indicating an indirect regulation that requires 
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newly synthesized proteins (Fig. 1b). RA activates the PI3K/Akt signaling pathway through 
a non-genomic mechanism (Lopez-Carballo et al., 2002; Masiá et al., 2007). Such activation is 
also required for the downregulation of the expression of LAMR1, since it did not occur in 
cells treated with RA in the presence of the PI3K inhibitor LY290004  (Fig. 1b). 
3.2 RA treatment reduces the presence of the 67-KDa Laminin receptor at the cell 
surface 
67LR is synthesized as a 37-KD precursor (37LRP) subunit, which is processed to the mature 
form of the protein on the cell surface (Buto et al., 1998; Landowski et al., 1995). Using 
antibodies recognizing the mature form of this protein in Western Blots (Wewer et al., 1987), 
we have detected that RA treatment results in a decrease on the levels of 67LR in cellular 
extracts of SH-SY5Y cells(Fig. 2A). By means of a monoclonal antibody specific for the 
37LRP (Buto et al., 1997), we observed a parallel reduction on the expression of the 
precursor protein (Fig. 2B). A similar RA-induced decrease in 67LR protein expression could 
be observed in another neuroblastoma cell line, LA-N-1 (Fig.2C). Immunofluorescent  
 
 
Fig. 1. (A-C) RA-induced downregulation of the expression of LAMR1. 
A. Northern Blot. Each lane contains 15 µg of total RNA from SH-SY5Y neuroblastoma cells 
treated with 1 µM RA for the times indicated in the figure. The blot was sequentially 
hybridized with [32P]-labeled DNA probes specific for the mRNAs of 67LR (LAMR1, 1.3 kb), 
and cyclophilin A (peptidyl- prolyl-isomerase A, PPIA, 1 Kb) as internal loading control.  
B. Northern Blot. Each lane contains 15 µg of total RNA from SH-SY5Y neuroblastoma cells 
pre-treated during 30 min with vehicle (-), Cycloheximide (CHX) or 10 µM  LY294002 (LY), 
and then treated with 1 µM RA (+) or vehicle (-) during 24 h  in the presence of the inhibitor. 
The blot was sequentially hybridized with [32P]-labeled DNA probes specific for the mRNAs 
of the 67LR (LAMR1, 1.4 Kb), and Actin- (ACTB, 2 Kb) as internal control. 
C. Quantitative analysis of the experiment shown in (B). The radioactivity present in each 
band on the blot was determined with a Fuji FLA5000 phosphorimager. The values obtained 
for LAMR1 probe were normalized with the corresponding ACTB values. The graph shows 
the average (bars) and standard deviation (error bars) of a duplicate experiments. 
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staining with the same antibody used on fig 2A, showed that 67LR is less abundant on the 
membranes of RA treated SH-SY5Ycells, as compared with untreated cells (Fig. 2D). 
3.3 RA treatment of neuroblastoma cells reduces migration towards and invasion 
through Matrigel 
Laminin is a basal membrane specific glycoprotein. Apart from its structural function, this 
protein presents a biological activity linked to adhesion, migration, growth and 
differentiation of certain cell types. Laminin is the major component of the commercial basal 
membrane preparation Matrigel (Kleinman & Martin, 2005, for review), that was used in the 
following experiments as source of laminin-rich matrix. RA has been reported to reduce the 
migratory, invasive and metastatic capacity of neuroblastoma cells in in vitro assays  
 
 
Fig. 2. (A-D) RA-induced reduction on the levels of the 67LR protein. 
A. Western Blot. Each lane contains 20 µg of protein extract from SH-SY5Y neuroblastoma 
cells treated with 1 µM RA for the times indicated in the figure. The blot was sequentially 
incubated with specific antibodies raised against 67LR protein, and with -actin antibodies 
(-ACT), as loading control. B. Western Blot. Each lane contains 20 µg of protein extract 
from SH-SY5Y neuroblastoma cells treated with 1 µM RA or vehicle for 72 h. The blot was 
sequentially incubated with a monoclonal antibody against the 37 KDa Laminin Receptor 
Precursor protein (37LRP), and with -actin antibodies (-ACT), as loading control. C. 
Western Blot. Each lane contains 20 µg of protein extract from LA-N-1 neuroblastoma cells 
treated with 1 µM RA for the times indicated in the figure. The blot was sequentially 
incubated with specific antibodies raised against 67LR protein, and with -actin antibodies 
(-ACT), as loading control. D. Immunofluorescence Microscopy. SH-SY5Y cells were 
treated during 96 h with 1 M RA or vehicle, scraped from the plate, and applied onto Poly-
lysine-coated slides. The slides were fixed with 4% paraformaldehyde in PBS, and 
sequentially incubated with rabbit Anti-67LR and FITC-conjugated anti-rabbit IgG. After 
washing with PBS, the slides were counter-stained with Hoechst 33258 and sequentially 
photographed in a Leica fluorescence microscope equipped with FITC- and UV-specific 
excitation filters. 
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(Joshi et al., 2006; Joshi et al., 2007; Meseguer et al., 2011; Voigt & Zintl, 2003). To look for 
RA-induced biological effects in neuroblastoma cells that could be related to the observed 
downregulation of the 67LR, we used assays for migration/haptotaxis towards Matrigel and 
for invasion through Matrigel. Migration and invasion assays described here were based on 
published methods (Albini et al., 1987; McCarthy et al., 1983), and conducted measuring the 
proportion of  calcein-labeled  migrating  cells in  modified  Boyden  chamber  assays,  using 
FluoroBlok light-opaque transwell inserts. Calcein-labeled SH-SY5Y cells (50,000 cells/well) 
were seeded onto the upper chamber of a FluoroBlok Insert in serum-free DMEM. For 
migration/haptotaxis assays, the lower chamber was coated with Matrigel (10 μg/cm2) and 
contained serum-free DMEM. (Fig. 3A). Similar experiments without Matrigel coating were 
set as negative controls for these experiments. Haptotaxis assays with neuroblastoma cells 
have shown increased migration when Matrigel is used as attractant. Surprisingly, short 
treatments with RA (24 h) resulted in a transient increase on cell migration that however 
occurred independently of the presence of chemoattractant. Treatment of SH-SY5Y cells  
 
 
Fig. 3. (A-D) RA treatment reduces migration towards and invasion through Matrigel. 
A. Schematic representation of the Haptotaxis/migration towards Matrigel assay. B. Effect of 
RA on cell migration towards Matrigel. Cells treated with 1 M RA as indicated or untreated 
controls were assayed in the absence (empty bars) or in the presence (grey bars) of Matrigel 
as chemoattractant, and the increase in fluorescence was measured. The graph shows the 
average +/- SD of triplicate experiments. The asterisks indicate a statistically significative 
difference between the corresponding sample and the untreated control without 
chemoattractant (ANOVA test; * p<0.05; ** p <0.01). C. Schematic representation of the 
invasion assay. D. Effect of RA on cell invasion through Matrigel. Cells treated with RA as 
indicated (grey bars) and their corresponding untreated controls (empty bars) were assayed, 
and the increase in fluorescence was measured. The graph shows the average +/- SD of 
triplicate experiments. The asterisks indicate a statistically significative difference between 
the sample and its untreated control. (ANOVA test;  * p<0.05). 
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with RA for 72 h reduced their migration rate and ablated the haptotactic attractive effect of 
Matrigel (Fig. 3B). For in vitro invasion assays the porous membrane separating both  
 
 
Fig. 4. (A-B) The 67-KDa laminin receptor is involved in migration towards and invasion 
through Matrigel.  
A. Effect of Laminin peptide P11 on cell migration towards Matrigel. Untreated cells (black 
bar), as well as cells treated with  scrambled peptide (grey bar) or P11 peptide (hatched bar) 
were assayed for migration using Matrigel as chemoattractant, together with a negative 
control experiment where the attractant was omitted (empty bar). The graph shows the 
average +/- SD of triplicate experiments. The asterisks indicate a statistically significative 
difference between the sample and its control. (ANOVA test;  * p<0.05). 
B. Effect of laminin peptide P11 on cell invasion through Matrigel. Untreated cells (black 
bar), as well as cells treated with scrambled peptide (grey bar) or P11 peptide (hatched bar) 
were used for in vitro Matrigel invasion assays. The graphs show the average +/- SD of 
triplicate experiments. The asterisks indicate a statistically significative difference between 
the sample and its control. (ANOVA test;  * p<0.05).  
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chambers of a FluoroBlok transwell was covered with Matrigel (5μg/cm2), simulating the 
basal membrane and 5% FBS was added to the lower chamber as chemoattractant (Fig. 3C). 
Similarly to what occurred with the migration assay, a transient increase on the invasive 
capacity of neuroblastoma cells was detected on Matrigel invasion assays after 24 h of RA 
treatment. Nevertheless, treatment with RA for 72 h resulted in strong reduction on the 
invasiveness of SH-SY5Y neuroblastoma cells (Fig. 3D). In the human neuroblastoma cell 
line LA-N-1 the effects of RA on migration/haptotaxis and in in vitro invasion were 
equivalent to those reported for SH-SY5Y cells (data not shown). 
3.4 The 67-KDa Laminin receptor is involved in migration towards and invasion 
through Matrigel 
The 67LR binds to the sequence CDPGYIGSR from the Laminin 1 chain (Graf et al., 1987b), 
and a peptide with that sequence (P11 peptide) impaired the activity of 67LR in vitro in  
laminin-mediated cell attachment and haptotaxis experiments (Graf et al., 1987a) and 
reduced the formation of experimental metastases in vivo (Iwamoto et al., 1987), probably by 
blocking the Laminin binding sites on 67LR. To assess the involvement of 67LR on the 
haptotaxis and invasiveness capacities of neuroblastoma cells, we have used P11 peptide to 
specifically block 67LR. Neuroblastoma cells were incubated with P11 peptide (60 g/ml), 
or a scrambled peptide of the same chemical composition but different amino acid sequence.  
Afterwards the cells were used either on migration/haptotaxis experiments or in in vitro 
invasion assays as above. The results obtained showed that incubation of SH-SY5Y cells 
with P11 peptide significatively reduced migration towards Matrigel, whereas addition of 
the scrambled control peptide had no relevant effect. (Fig. 4A).  
Similarly, addition of peptide P11 also reduced the invasion of neuroblastoma cells through 
Matrigel, whereas incubation with the control peptide had no remarkable effect on invasion 
(Fig. 4B). These results indicate the involvement of 67LR on laminin-induced 
migration/haptotaxis and in invasion through Matrigel-coated filters. Taken together, our 
results strongly support that RA-induced downregulation of 67LR contributes to the 
observed reduction of the biological aggressiveness of neuroblastoma cells after RA 
treatment. 
3.5 Expression of the 67-KDa Laminin receptor in human neuroblastoma tumors 
The expression of 67LR in human neuroblastoma primary tumors was tested by 
immunocytochemistry with the same 67LR antibody used for Western Blots and Expression 
of 67LR in neuroblastoma tumor samples was analyzed by immunohistochemistry with 
anti-67LR antibodies. The graph shows the percentage of the analyzed neuroblastoma 
samples (n=60) showing weak or no signal (empty sector), moderate intensity signal 
(hatched sector) or strong signal (black sector). 
immunofluorescence. The antibody provided good results with paraffin sections, showing 
specific staining on epithelial tissues and invasive carcinomas used as positive controls (data 
not shown). Paraffin sections of a tissue microarray including 49 high-risk primary 
neuroblastoma tumor samples, including40 cases with MYCN amplification (100 to 500 
copies per haploid genome) and 9 cases with MYCN gain (2 to 4 copies per haploid 
genome), and complete sections from 11 additional poorly differentiated neuroblastoma 
tumors were analyzed. From these 60 different human primary neuroblastoma samples 17 
showed no or weak signal (28.33%), 22 showed positive staining with moderate intensity 
signal (36.67%), and 21 (35%) showed strong signal (Fig. 5). 
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Fig. 5. Expression of 67LR in neuroblastoma tumor samples. 
Photomicrographs of representative neuroblastoma tumor sections stained for 67LR are 
shown in Figure 6, including sections showing no signal (Fig. 6A), weak signal (Fig 6B), 
moderate intensity signal (Fig. 6 C and D), and strong signal (Fig. 6 E and F). Nuclear 
staining was detected in these strongly labeled tumor sections, which is an unexpected 
location for 67LR. Nevertheless, it has to be noted that shedding of 67LR by tumor cells has 
been reported (Berno et al., 2005; Karpatova et al., 1996; Moss et al., 2006), and it appears 
 
 
Fig. 6. (a-f) Immunohistochemical detection of 67LR in neuroblastoma tumor samples. 
Photomicrographs of representative neuroblastoma tumor paraffin sections stained for 67LR 
antibody and counterstained with hematoxylin, including sections showing no signal (A), 
weak signal (B), moderate intensity signal (C and D),  and strong signal (E and F).\ 
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conceivable that artefactual location of shed 67LR molecules could occur during the fixation 
and inclusion procedures. In summary, over 71% of the assayed neuroblastoma samples 
showed expression of 67LR by immunocytochemistry, with a full range of expression levels. 
4. Discussion 
The 67LR has been involved in the biological aggressiveness of tumor cells, by helping to 
laminin remodeling and favoring its degradation by proteolytic enzymes (Ardini et al., 2002; 
Berno et al., 2005; Vande Broek et al., 2001). Remodeling of the tumor microenvironment and 
degradation of basement membrane components are two crucial steps in the development of 
metastases (Wang et al., 2005b). Here we show that RA treatment of neuroblastoma cells 
results in a reduction of the expression of 67LR. Concomitant to the downregulation of 67LR, 
RA treatments result in a reduction in cell migration towards Matrigel and an impairment in 
neuroblastoma cells invasiveness in in vitro assays. Finally, the involvement of 67LR in 
migration and invasion of neuroblastoma cells is supported by experiments in which 
impairment of the 67LR activity by laminin-derived P11 peptide results in reduced migration 
and invasion capacities for neuroblastoma cells. Taken together all these results support the 
idea that RA-induced downregulation of 67LR would account for the observed reductions of 
the migration capacity and invasiveness in vitro, and therefore would contribute of a marked 
reduction of the biological aggressiveness of neuroblastoma cells. RA treatments have been 
shown to be effective for the therapy of human neuroblastoma, especially in avoiding relapse 
when applied in a context of minimal residual disease after intensive therapies (Matthay & 
Reynolds, 2000; Reynolds et al., 2003) The reduction of the ability of migrating towards the 
basement membrane and degrading it would fit into the range of actions that would lead to 
effective therapeutic effects in that context. 
Several lines of evidence suggest that the 67LR could be a useful therapeutic target for 
cancer treatment. The anti-cancer cytokines TNF and IFN downregulate the expression of 
67LR in transformed keratinocytes (Clausse et al., 1998). Blocking of 67LR with specific 
antibodies or laminin peptides, or downregulating its expression by anti-sense RNA leads to 
decreased migration and invasiveness in vitro to reduced metastatic and angiogenic 
potentials in different experimental metastasis models (Iwamoto et al., 1987; Narumi et al., 
1999; Satoh et al., 1999; Tanaka et al., 2000) 
Remarkably, short term RA treatments induce a transient increase in neuroblastoma cell 
migration and invasion in vitro. The increase in migration appears to be nonspecific, since 
also occurs in the absence of laminin chemoattractant. Similar RA-induced rapid transient 
increases in migration and invasion in neuroblastoma cells have been reported (Joshi et al., 
2006; Meseguer et al., 2011), and correlated to the expression of tissue transglutaminase 
(Joshi et al., 2006). Blocking of RA signaling in vivo also impaired neuroblast migration from 
the subventricular zone of the brain to the olfactory bulb (Wang et al., 2005a), suggesting 
that short term RA-induced increases in migration probably reflects a physiological feature 
of RA action on the regulation of neurogenesis. Coupling of differentiation with migration 
has been described for mouse cortical neurons and the involvement of proneural bHLHs 
transcription factors in migration has been proposed (Ge et al., 2006). Remarkably, RA 
treatment of neuroblastoma cells results in changes in the expression patterns of bHLH 
factors including induction of proneural bHLH factors like NEUROD6 and NEUROD1 (Jogi 
et al., 2002; Lopez-Carballo et al., 2002). 
Another important aspect is the mechanism through which RA induces the downregulation 
of LAMR1 gene, which appears to be complex. It has reported that LAMR1 is downregulated 
by p53, through an AP-2 binding element located in its first intron (Modugno et al., 2002). It 
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is noteworthy that RA treatment of N1E-115 neuroblastoma cells results in the induction of 
p73, a protein structurally and functionally related to p53 (De Laurenzi et al., 2000).In 
addition, accumulation of transactivation-deficient DeltaN-p73 in undifferentiated 
neuroblastic tumors has been reported (Douc-Rasy et al., 2002). Recently it has been 
reported that 67LR is a hypoxia-inducible factor target gene in gastric cancer (Liu et al., 
2010). In neuroblastoma the hypoxia-inducible factors play an important role in maintaining 
an undifferentiated stem cell-like phenotype, that correlates with poor outcome (Holmquist-
Mengelbier et al., 2006; Noguera et al., 2009; Pietras et al., 2009; Pietras et al., 2010). 
Finally, we show that more than 71% of the high-grade primary neuroblastoma samples 
expressed 67LR as revealed by immunocytochemical analysis. The striking differences found 
in the expression levels of 67LR among the samples open the possibility that these differences 
could reflect diversity in biological aggressiveness of the tumor cells that may contribute to the 
differences in the clinical outcome and the heterogeneity of the therapeutic response. 
5. Conclusion 
RA-induced downregulation of 67LR correlates with a reduction in the biological 
aggressiveness in vitro of neuroblastoma cells, and supports the idea of 67LR as an 
important molecular target for the therapeutic actions of RA in neuroblastoma. 
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